We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why LeMaitre Vascular (LMAT) Could Be Positioned for a Surge
Read MoreHide Full Article
LeMaitre Vascular, Inc. (LMAT - Free Report) is a medical devices and implants provider that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on LMAT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that LeMaitre Vascular could be a solid choice for investors.
Current Quarter Estimates for LMAT
In the past 30 days, four estimates have gone higher for LeMaitre Vascular while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 17 cents a share 30 days ago, to 20 cents today, a move of 17.6%.
Current Year Estimates for LMAT
Meanwhile, LeMaitre Vascular’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 70 cents per share 30 days ago to 79 cents per share today, an increase of 12.9%.
The stock has also started to move higher lately, adding 16.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Why LeMaitre Vascular (LMAT) Could Be Positioned for a Surge
LeMaitre Vascular, Inc. (LMAT - Free Report) is a medical devices and implants provider that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on LMAT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that LeMaitre Vascular could be a solid choice for investors.
Current Quarter Estimates for LMAT
In the past 30 days, four estimates have gone higher for LeMaitre Vascular while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 17 cents a share 30 days ago, to 20 cents today, a move of 17.6%.
Current Year Estimates for LMAT
Meanwhile, LeMaitre Vascular’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 70 cents per share 30 days ago to 79 cents per share today, an increase of 12.9%.
LeMaitre Vascular, Inc. Price and Consensus
LeMaitre Vascular, Inc. Price and Consensus | LeMaitre Vascular, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 16.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>